Sweden Pharmaceuticals & Healthcare Report Q1 2013 - New Market Report Now Available
BMI View: We remain of the opinion that Sweden's overall pharmaceutical market value will decline over the forecast period to 2016, both in local currency and US dollar terms. We base our view on patent expiration and cost containment policies, which will continue to stimulate consumption of cheaper generic medicines. Moreover, in the short term, weak consumer confidence in Sweden may affect the growth of its non-prescription market, while - in the longer-term - we expect a drop in consumers'...
View full press release